Best Peptides for Immune System Research UK 2026

The immune system comprises two interlocking arms: the fast-responding innate immune system (neutrophils, macrophages, NK cells, DCs, mast cells, complement, pattern recognition receptors) and the slower but antigen-specific adaptive immune system (T and B lymphocytes, immunological memory). Research into immune biology spans scales from atomic resolution of receptor-ligand interactions (TCR-pMHC structures, antibody paratope-epitope contacts) to whole-organism immune reconstitution. Understanding how peptide research compounds modulate specific nodes in the immune circuit — innate activation, lymphocyte differentiation, cytokine signalling, tolerogenic mechanisms — provides mechanistic tools applicable across infection, autoimmunity, allergy, cancer immunology, and transplantation research.

Clinical evidence for peptide-based visceral fat reduction comes primarily from three compound categories: growth hormone secretagogues, GLP-1 receptor agonists, and selective reuptake inhibitors. Each category addresses a different aspect of the cortisol-fat axis, and the strongest protocols often combine mechanisms rather than relying on a single peptide. Growth hormone secretagogue protocols. Typically combining CJC-1295 (a GHRH analog with extended half-life) and Ipamorelin (a selective ghrelin receptor agonist). Are dosed subcutaneously at 200–300mcg per compound, administered before bed to align with natural GH pulse timing. Research conducted at the University of Virginia School of Medicine found that combined GHRH/ghrelin agonist therapy increased peak GH secretion by 4–6 fold compared to baseline, with corresponding reductions in visceral adiposity measured by DEXA scan at 12 and 24 weeks. The fat loss observed was region-specific: abdominal circumference decreased by 4.2cm on average, while subcutaneous fat measurements showed minimal change. GLP-1 protocols for visceral fat target insulin resistance directly. Semaglutide at therapeutic doses (2.4mg weekly subcutaneous) produced visceral fat reductions of 8.5% at 68 weeks in the STEP-1 trial, compared to 3.1% with placebo. The difference reflects direct metabolic effects beyond weight loss alone. GLP-1 agonists slow gastric emptying and extend satiety signaling, but their impact on visceral fat comes from improved hepatic insulin sensitivity and reduced gluconeogenesis, which decreases the hormonal drive to store abdominal fat even in caloric maintenance states. Our experience working with researchers in this field shows that peptide selection must match the underlying driver. If cortisol elevation is chronic and stress-driven, growth hormone restoration is critical. If insulin resistance dominates the picture. Fasting glucose above 100mg/dL, HbA1c creeping toward 5.7%. GLP-1 mechanisms become essential.